Skip to main content
Premium Trial:

Request an Annual Quote

Tango Therapeutics Scraps USP1 Inhibitor Trial Due to Toxicities

NEW YORK – Tango Therapeutics said Thursday that it will stop developing its USP1 inhibitor TNG348 due to the toxicities it caused patients in a clinical trial. 

Boston-based Tango had been studying TNG348 in a Phase I/II trial in patients with cancers harboring BRCA1/2 and other homologous recombination repair deficiency mutations. But after eight weeks, the trial's investigators observed grade 3 and 4 liver function abnormalities in patients receiving the drug and decided to stop the study. 

The trial was designed to evaluate TNG348 as both a single agent and in combination with Merck and AstraZeneca's PARP inhibitor Lynparza (olaparib). None of the patients had received the combination regimen yet when Tango decided to discontinue the study. 

"While disappointing, we believe this is the right decision given the data at hand," Tango President and CEO Barbara Weber said in a statement. "We will focus resources and capital on our existing portfolio, particularly our PRMT5 program." 

According to Weber, the firm will deliver a comprehensive clinical update on TNG908 and TNG462, two PRMT5 inhibitors it is developing in MTAP-deleted cancers, in the second half of the year. Tango also said its cash runway extends into 2027.